ALNYLAM PHARMACEUTICALS, INC.·4

Dec 23, 5:00 PM ET

MARAGANORE JOHN 4

4 · ALNYLAM PHARMACEUTICALS, INC. · Filed Dec 23, 2021

Insider Transaction Report

Form 4
Period: 2021-12-21
MARAGANORE JOHN
DirectorCEO
Transactions
  • Award

    Common Stock

    2021-12-21+14,167234,299 total
  • Tax Payment

    Common Stock

    2021-12-22$189.13/sh6,315$1,194,356227,984 total
  • Tax Payment

    Common Stock

    2021-12-22$190.50/sh2$381227,982 total
  • Tax Payment

    Common Stock

    2021-12-22$186.02/sh319$59,340227,663 total
Holdings
  • Common Stock

    (indirect: by Managed Account)
    3,133
Footnotes (3)
  • [F1]On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021.
  • [F2]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
  • [F3]Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT